Latest 10-K annual reports

National Storage Affiliates Trust reported a 2.3% decrease in total revenue for 2025, primarily due to lower occupancy and property dispositions, alongside increased management fees and operating expenses.

TopBuild Corp. reported a 1.5% increase in net sales for 2025, driven by strategic acquisitions, despite a decline in overall sales volume and compressed margins.

Permian Resources Corporation reported increased production and strategic acquisitions in 2025, alongside a corporate reorganization and debt management, despite lower oil and NGL prices.

Frontdoor, Inc. announced significant revenue and Adjusted EBITDA increases for 2025, largely propelled by the 2-10 HBW acquisition, despite a slight decline in its core home warranty customer base.

Confluent, Inc. filed an amendment to its 2025 Annual Report on Form 10-K to provide comprehensive details on executive compensation, corporate governance, and related party transactions.

Revelation Biosciences, a clinical-stage biotech, reported recurring losses and a going concern qualification, despite advancing its kidney disease drug candidates and recent capital raises.

Ramaco Resources reports a net loss in 2025 amidst softening metallurgical coal markets, while aggressively funding its strategic rare earth elements and critical minerals development.

Adeia Inc. announced an 18% increase in total revenue to $443.4 million for fiscal year 2025, driven by significant non-recurring licensing agreements, despite a decrease in cash from operations.

Maravai LifeSciences reported a significant revenue decrease and net loss in 2025, driven by reduced CleanCap sales and substantial impairment charges, while implementing a major corporate realignment.

Kimbell Royalty Partners achieved significant production and reserve growth in 2025, driven by strategic acquisitions and increased natural gas prices, despite a decline in oil prices.

United States Lime & Minerals, Inc. reported significant revenue and net income growth in 2025, driven by increased sales volumes and higher selling prices, while advancing its major Texas kiln project.

Intellia Therapeutics' 2025 annual report highlights significant progress for its HAE program with anticipated 2027 launch, while its ATTR program faces a clinical hold and substantial net losses continue.

Biodesix, Inc. announced a 24% increase in total revenue for fiscal year 2025, reaching $88.5 million, driven by growth in lung diagnostic testing and development services, while also extending its senior secured term loan maturity to November 2028.

Rocket Pharmaceuticals announced a strategic corporate reorganization to focus on its AAV cardiovascular gene therapy platform, de-prioritizing other programs, and successfully resubmitted its Biologics License Application for KRESLADI.

Cars.com Inc. reported a 1% increase in total revenue to $723.2 million for fiscal year 2025, while net income significantly decreased by 58% to $20.1 million.

Expensify, Inc. reported a net loss of $21.39 million for fiscal year 2025, driven by increased marketing spend and legal settlement costs, despite a slight revenue increase.

PROCEPT BioRobotics Corporation announced significant revenue growth in its 2025 annual report, driven by increased adoption and utilization of its robotic systems for BPH treatment, despite continued net losses.

Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company, reported a net loss of $285.4 million in 2025 despite significant revenue growth from its two FDA-approved cancer therapies, Revuforj and Niktimvo.

Fortrea Holdings Inc. reports a significant net loss of $986.2 million in 2025, primarily driven by a substantial goodwill impairment charge, despite a slight revenue increase.

BioCryst Pharmaceuticals achieved significant revenue growth and profitability in 2025, driven by ORLADEYO sales and strategic acquisitions, while expanding its rare disease pipeline.

Indivior Pharmaceuticals reports strong 2025 revenue growth driven by SUBLOCADE, alongside strategic restructuring and U.S. domestication.

Repligen Corporation announced a 16.4% increase in product revenue for 2025, reaching $737.96 million, alongside the remediation of a material weakness in revenue recognition but ongoing challenges with IT general controls and inventory valuation.

OUTFRONT Media reported mixed 2025 results, with organic revenue growth and improved OIBDA, driven by digital expansion and transit segment recovery, despite a net income decline due to prior year's asset sale and restructuring costs.

MidCap Financial Investment Corporation reported a decrease in net assets and earnings per share for 2025, despite increased investment income and strategic debt refinancing.

Integra LifeSciences reported a significant net loss of $516.5 million for 2025, primarily due to a $511.4 million goodwill impairment charge, alongside ongoing quality system challenges and increased tariff costs.

Montrose Environmental Group reports significantly reduced net loss and robust revenue growth in 2025, driven by organic expansion and emergency response services.

Alliance Resource Partners reports a 10.4% revenue decrease in 2025, driven by lower coal prices, while strategically investing in oil & gas and energy technologies.

Clipper Realty Inc. reports a significant net loss in 2025, driven by property sale losses, impairment charges, and ongoing defaults and lease termination issues with its commercial properties in New York City.

Spok Holdings, Inc. reports a 1.5% increase in total revenue for 2025, driven by strong software growth, while managing the ongoing decline in wireless services.

UMB Financial Corporation announced significant financial growth in 2025, driven by its acquisition of Heartland Financial USA, Inc., leading to increased net income and expanded market presence.